Previous 10 | Next 10 |
AbCellera, the stock, has had a woeful two plus years as a public company; however, AbCellera the business is performing brilliantly. The company recently announced an internally developed T-Cell engager program that it is looking to partner, likely at attractive terms for AbCellera, ...
AbCellera (Nasdaq: ABCL) will announce its first quarter 2022 financial results on Tuesday, May 10, 2022, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through...
AbCellera (Nasdaq: ABCL), a technology company focused on next-generation antibody discovery, today announced the release of data on its new T cell engager platform at the American Association for Cancer Research (AACR) 2022 Annual Meeting. AbCellera’s poster presentation des...
Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...
Stanley Druckenmiller’s 13F portfolio value decreased from $3.08B to $2.76B this quarter. Duquesne increased Coupang, Carvana, Kbr, Flex, Procept Bio, and Smartsheet while decreasing Alphabet, Amazon.com, Palo Alto Networks, Starbucks, and Expedia Group. They also dropped Meta ...
The following slide deck was published by AbCellera Biologics Inc. in conjunction with this event. For further details see: AbCellera Biologics (ABCL) Investor Presentation - Slideshow
Atreca (BCEL -31.9%) stock has fallen dramatically today after the stock rose nearly 211% on March 4 following the release of quarterly earnings after the bell the day before. The company missed on the bottom line in its Q4 2021 results. As of 1222p ET, ~7.7M shares had traded ...
A disagreement between Republican senators and the White House over funding for COVID-19 therapeutics and vaccines could imperil the Biden administration’s efforts to provide pandemic relief for Americans this year. The dispute stems from the level of transparency provided by the gover...
Insiders selling Airbnb despite the recent pullback. Co-founder Joe Gebbia significantly increased his selling of Airbnb last week. With the recent pullback in the stock, Airbnb now trades at a trailing EV/sales of 14.11 and a forward EV/sales of 10.66. For further details s...
Image source: The Motley Fool. AbCellera Biologics Inc. (NASDAQ: ABCL) Q4 2021 Earnings Call Feb 24, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: AbCellera Biologics Inc. (ABCL) Q4 2021 Earnings Call Transcript ...
News, Short Squeeze, Breakout and More Instantly...
AbCellera Biologics Inc. Company Name:
ABCL Stock Symbol:
NASDAQ Market:
AbCellera Biologics Inc. Website:
AbCellera (Nasdaq: ABCL) will announce its second quarter 2024 financial results on Tuesday, August 6, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link t...
2024-06-13 05:40:00 ET Discovering new drugs can be a lucrative endeavor, but things aren't working out lately for AbCellera Biologics (NASDAQ: ABCL) . Shares of this unusual biotech stock are down by about 57% from the high water mark they set last summer. The steep losses migh...
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024, at 12:20 p.m. Pacific Time (3:20 p.m. Eastern Time). A live audio webcast of the presentation may be accessed throug...